Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR

Yiheng Capital Management L.P. decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 13.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,440 shares of the company’s stock after selling 10,000 shares during the period. Kymera Therapeutics comprises approximately 2.5% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 11th biggest holding. Yiheng Capital Management L.P.’s holdings in Kymera Therapeutics were worth $7,275,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares in the last quarter. Invesco Ltd. boosted its position in Kymera Therapeutics by 13.8% during the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after purchasing an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in Kymera Therapeutics in the second quarter valued at about $265,000.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $118.15 on Monday. Kymera Therapeutics, Inc. has a fifty-two week low of $39.84 and a fifty-two week high of $130.05. The firm has a market capitalization of $9.82 billion, a price-to-earnings ratio of -36.47 and a beta of 1.95. The stock’s 50-day simple moving average is $112.78 and its 200-day simple moving average is $93.71.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. Kymera Therapeutics’s revenue was up 465.2% on a year-over-year basis. During the same period last year, the firm posted ($0.95) EPS. As a group, equities analysts forecast that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Insider Activity

In related news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This represents a 86.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Noah Goodman sold 3,389 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the completion of the transaction, the insider owned 47,179 shares of the company’s stock, valued at $5,392,087.91. This trade represents a 6.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,587,629 shares of company stock valued at $386,183,782. 15.98% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Canaccord Genuity Group boosted their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Bank of America raised their price target on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Truist Financial boosted their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Barclays increased their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Mizuho raised their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.17.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.